Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib

References

• Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933–980.
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–830.
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315: 550–554.
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 2003;349: 1451–1464.
   PubMed Web of Science ®Google Scholar
• Socialstyrelsen. Cancerstatistik. Vol. 2012; 2011. Available from: www.Socialstyrelsen.se/statistik
   Google Scholar
• Blodcancerregistret, Nationellt register för Kronisk Myeloisk Leukemi (KML). Redovisning av material 2002-2008. Regionalt Onkologiskt Centrum i Uppsala/Örebroregionen. Uppsala: Regionalt Onkologiskt Centrum; 2010.
   Google Scholar
• Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia:a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514–2520.
   PubMed Web of Science ®Google Scholar
• Wedelin C, Bjorkholm M, Mellstedt H, et al. Clinical findings and prognostic factors in chronic myeloid leukemias. Acta Med Scand 1986;220:255–260.
   PubMed Web of Science ®Google Scholar
• Axdorph U, Stenke L, Grimfors G, et al. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase—a report from the Swedish CML Group. Br J Haematol 2002;118:1048–1054.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999;17:284–292.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Breitscheidel L. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. J Med Econ 2008;11:571–584.
   PubMedGoogle Scholar
• Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515–526.
   PubMed Web of Science ®Google Scholar
• Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574–2583.
   PubMed Web of Science ®Google Scholar
• Reed SD, Anstrom KJ, Li Y, et al. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008;26:435–446.
   PubMed Web of Science ®Google Scholar
• Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005;25:325–334.
   PubMed Web of Science ®Google Scholar
• Socialstyrelsen. Dödsorsaksstatistik. 2011. Available from www.Socialstyrelsen.se/statistik
   Google Scholar
• LFN. General Guidelines for Economic Evaluation from the Pharmaceutical Benefits Board. 2003. Available from: www.tlv.se/
   Google Scholar
• (LIF) SAotPI. FASS (pharmaceutical specialities). Stockholm: LIF; 2011. Available from: www.ispor.org/peguidelines/source/Guidelines_in_Sweden.pdf
   Google Scholar
• Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care. 1994;10:683–694.
   PubMedGoogle Scholar
• Statistiska centralbyrån. Statistics Sweden population statistics. 2012. Available from: http://www.scb.se
   Google Scholar
• Statistiska centralbyrån. Statistics Sweden consumers price index. Stockholm. 2012. Available from: http://www.scb.se
   Google Scholar
• Ekman M. Studies in health economics: modelling and data analysis of costs and survival. Stockholm: Stockholm School of Economics; 2002.
   Google Scholar
• EuroQol. What is EQ-5D? 2012. Available from: www.euroqol.org/eq-5d/what-is-eq-5d.html
   Google Scholar
• van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. A prospective randomised trial. Eur J Cancer 2001;37:1781–1789.
   PubMed Web of Science ®Google Scholar
• Bieri S, Roosnek E, Helg C, et al. Quality of life and social integration after allogeneic hematopoietic SCT. Bone Marrow Transplant 2008;42:819–827.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007;25:191–195.
   PubMed Web of Science ®Google Scholar
• Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. Int J Cancer 2007;121:2260–2266.
   PubMed Web of Science ®Google Scholar
• Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305–313.
   PubMed Web of Science ®Google Scholar
• Jonsson S, Olsson B, Soderberg J, et al. Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study. Ann Hematol 2012;91:679–685.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Saglio G, Radich J, et al. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk 2012;12:223–229.
   PubMed Web of Science ®Google Scholar
• Oyekunle A, Klyuchnikov E, Ocheni S, et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011;126:30–39.
   PubMed Web of Science ®Google Scholar
• Goulden S, Sutcliffe F, Stevens A. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib. Lancet Oncol 2012;13:127–128.
   PubMed Web of Science ®Google Scholar
• Morris RH. Thriving with chronic myeloid leukaemia. Lancet 2001;358(Suppl.): S12.
   PubMedGoogle Scholar